Over the full course of SPARTHACUS, SPARTHA Medical delivered major innovations advancing antimicrobial technologies, device coatings, and clinical systems.
The main breakthrough was a handheld dual-component spray device applying supramolecular antimicrobial membranes directly on living tissues. Validated in four preclinical models, it showed infection prevention plus added benefits in wound healing, pain reduction, and mobility recovery. A patent was filed, and a cosmetic version tested safely in humans.
In parallel, a functional industrial prototype was developed for large-scale coating, enabling integration into partners’ manufacturing lines and attracting multinational interest.
SPARTHA also created a biopolymer-based hydrogel with antimicrobial, antiviral, and antifungal activity, providing a safe, eco-friendly alternative to conventional disinfectants. A patent was filed, with initial applications in sexual protection and contact lens coatings.
To accelerate R&D, SPARTHA built AI-driven in silico models predicting immunomodulatory and antibiofilm properties. These generated synthetic peptides (Pep7, Pep9, Pep11) validated with strong efficacy and low cytotoxicity; a patent is in preparation.
The spray device design evolved with clinician and engineer input, improving ergonomics, lowering contamination risk, and enabling mass production. A key connector innovation ensured fine mist and consistent coating.
Beyond medical use, a cosmetic proof-of-concept showed polymer sprays improved hydration, shine, and frizz control on hair without adverse effects, supporting future consumer health applications.
SPARTHA’s IP strategy secured 7 patent filings and 3 pending applications, covering compositions, devices, AI peptides, and product-specific claims, ensuring freedom to operate and supporting commercialization.
Together, these achievements position SPARTHA as a pioneer in smart antimicrobial technologies, with innovations ready for clinical trials, industrial deployment, and market entry.
